X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1260) 1260
Publication (131) 131
Book Review (25) 25
Book Chapter (13) 13
Magazine Article (4) 4
Book / eBook (2) 2
Dissertation (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (828) 828
index medicus (686) 686
moderate (578) 578
dementia (488) 488
male (449) 449
alzheimer's disease (442) 442
aged (413) 413
female (401) 401
double-blind (333) 333
clinical neurology (321) 321
neurosciences (320) 320
donepezil (311) 311
alzheimer disease - drug therapy (286) 286
memantine (269) 269
psychiatry (267) 267
moderate alzheimers-disease (254) 254
middle aged (235) 235
geriatrics & gerontology (229) 229
aged, 80 and over (227) 227
pharmacology & pharmacy (214) 214
efficacy (199) 199
alzheimers-disease (195) 195
animals (186) 186
placebo-controlled trial (171) 171
cholinesterase inhibitors - therapeutic use (160) 160
treatment outcome (159) 159
memantine - therapeutic use (149) 149
cognition (125) 125
neuropsychological tests (125) 125
brain (121) 121
rivastigmine (119) 119
galantamine (116) 116
gerontology (116) 116
analysis (113) 113
research (111) 111
adult (106) 106
memory (105) 105
alzheimers disease (104) 104
drug therapy (102) 102
neurology (98) 98
care and treatment (97) 97
indans - therapeutic use (96) 96
piperidines - therapeutic use (96) 96
severity of illness index (96) 96
cholinesterase-inhibitors (94) 94
activities of daily living (93) 93
mild cognitive impairment (92) 92
nootropic agents - therapeutic use (89) 89
clinical trials (88) 88
safety (88) 88
alzheimer disease - psychology (87) 87
risk factors (87) 87
dementia - drug therapy (86) 86
medicine, general & internal (84) 84
diagnosis (81) 81
double-blind method (81) 81
randomized controlled-trial (80) 80
cholinesterase inhibitors (76) 76
randomized controlled trials as topic (75) 75
health aspects (74) 74
cognitive impairment (71) 71
alzheimer disease - diagnosis (70) 70
excitatory amino acid antagonists - therapeutic use (70) 70
prevalence (70) 70
controlled-trial (69) 69
aging (68) 68
cognition - drug effects (67) 67
alzheimer disease (65) 65
cognitive ability (65) 65
rats (64) 64
mild (63) 63
psychology (62) 62
vascular dementia (62) 62
impairment (61) 61
alzheimer’s disease (60) 60
quality of life (60) 60
traumatic brain injury (60) 60
article (59) 59
mice (58) 58
studies (58) 58
review (56) 56
severe alzheimers-disease (56) 56
disease progression (55) 55
time factors (54) 54
moderate vascular dementia (53) 53
internal medicine (52) 52
exercise (51) 51
disease (50) 50
dose-response relationship, drug (50) 50
risk (50) 50
caregivers (49) 49
dementia - psychology (49) 49
medical research (49) 49
neurodegenerative diseases (49) 49
rehabilitation (49) 49
therapy (49) 49
medicine (48) 48
older-adults (48) 48
oxidative stress (48) 48
cognition disorders - drug therapy (47) 47
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1208) 1208
German (20) 20
Russian (15) 15
French (12) 12
Spanish (12) 12
Japanese (3) 3
Portuguese (2) 2
Turkish (2) 2
Czech (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NEUROLOGY, ISSN 0028-3878, 08/2015, Volume 85, Issue 8, pp. 692 - 700
Objective: To evaluate the effects of bapineuzumab on brain beta-amyloid (A beta) burden using C-11-Pittsburgh compound B (C-11-PiB)-PET. Methods: Two phase 3... 
MODERATE ALZHEIMERS-DISEASE | BRAIN | CLINICAL NEUROLOGY
Journal Article
Alzheimer's Research and Therapy, ISSN 1758-9193, 06/2016, Volume 8, Issue 1, p. 22
Journal Article
BMC Geriatrics, ISSN 1471-2318, 11/2016, Volume 16, Issue 1, pp. 1 - 10
Background: Alzheimer's disease (AD), the commonest cause of dementia, represents a significant cost to UK society. This analysis describes resource... 
AD dementia severity | Societal costs | Alzheimer's disease | MMSE | Clinical outcomes | Resource use | TRIALS | MODERATE | MINI-MENTAL-STATE | DEMENTIA | SOLANEZUMAB | CARE | GERIATRICS & GERONTOLOGY | EUROPEAN COUNTRIES | GERONTOLOGY | Complications and side effects | Care and treatment | Utilization | Analysis | Medical care | Research | Risk factors | Dementia
Journal Article
JAMA Neurology, ISSN 2168-6149, 09/2018, Volume 75, Issue 9, pp. 1045 - 1046
Journal Article
Chemical Communications, ISSN 1359-7345, 2017, Volume 53, Issue 7, pp. 1289 - 1292
By combining KLVFF peptide and self-assembly chaperone we fabricate a new system to achieve the synchronization between Ab fibril disaggregation and reducing... 
IMMUNIZATION | MEMORY | IMMUNOTHERAPY | MOLECULAR CHAPERONES | NEURODEGENERATION | MECHANISMS | MODERATE ALZHEIMERS-DISEASE | CHEMISTRY, MULTIDISCIPLINARY | AGGREGATION | PEPTIDE | BRAIN
Journal Article
JAMA, ISSN 0098-7484, 05/2015, Volume 313, Issue 19, pp. 1939 - 1950
Journal Article
Journal of Psychiatric Research, ISSN 0022-3956, 11/2019, Volume 118, pp. 31 - 37
The cost-effectiveness of both cholinesterase inhibitors and memantine by delaying nursing home placement has been supported by numerous studies. The... 
DONEPEZIL | MORTALITY | RIVASTIGMINE | PSYCHIATRY | PERSISTENCE | PREDICTORS | GALANTAMINE | MODERATE ALZHEIMERS-DISEASE | CHOLINESTERASE-INHIBITORS | MEMANTINE | ADHERENCE
Journal Article
Journal Article
NATURE REVIEWS NEUROLOGY, ISSN 1759-4758, 01/2016, Volume 12, Issue 1, pp. 11 - 13
The recent DOMINO-AD trial suggests that continued treatment with donepezil delays nursing home placement for patients with severe Alzheimer disease, but more... 
MODERATE | CHOLINESTERASE-INHIBITORS | MEMANTINE | ALZHEIMERS-DISEASE | CLINICAL NEUROLOGY
Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 11/2017, Volume 16, Issue 12, pp. 863 - 883
Journal Article
Journal Article